HI PHARMACEUTICAL LTD

Company number SC721693 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

HI PHARMACEUTICAL LTD - Analysis Report

Company Number: SC721693

Analysis Date: 2025-07-29 19:12 UTC

  1. Risk Rating: MEDIUM
    The company shows a significant decline in net current assets and net assets over the most recent year, indicating potential solvency and liquidity concerns. However, it remains solvent on a balance sheet basis with positive net assets.

  2. Key Concerns:

  • Declining Net Current Assets: Net current assets dropped from £9,637 in 2023 to £2,425 in 2024, suggesting reduced liquidity.
  • Small Scale Operation: Micro-entity status with only one employee and limited asset base implies vulnerability to operational disruptions or cash flow volatility.
  • Single Director and PSC Concentration: The sole director and 100% controlling shareholder is the same individual, which could pose governance and succession risks.
  1. Positive Indicators:
  • Compliance with Filing Requirements: All statutory accounts and confirmation statements are up to date with no overdue filings.
  • Solvent Position: Despite decline, the company maintains positive shareholder funds and net assets, indicating it can currently meet liabilities.
  • Clear Ownership and Control: Ownership and control are transparent, reducing risks related to hidden interests or complex structures.
  1. Due Diligence Notes:
  • Investigate reasons behind the sharp reduction in current assets and net assets over the 2024 financial year.
  • Review cash flow statements and working capital management to assess liquidity trends and ability to meet short-term obligations.
  • Confirm operational viability given the micro-entity scale and single employee structure, including any plans for scaling or diversification.
  • Assess director’s background and capability, given sole control, and any related-party transactions or risks.
  • Verify that no undisclosed contingent liabilities or regulatory issues exist, as none are evident from current filings.

Perspective: Investment Risk Assessor · Model: gpt-4.1-mini · Generated 29 July 2025

Sign in to generate a free AI analysis of this company — no password needed, just an email link.